125 related articles for article (PubMed ID: 38924461)
1. Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence.
Bawa S; Wondimu A; Postma MJ; Hutubessy R; van Hulst M
Expert Rev Vaccines; 2024; 23(1):655-673. PubMed ID: 38924461
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
3. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
4. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
[TBL] [Abstract][Full Text] [Related]
5. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
[TBL] [Abstract][Full Text] [Related]
6. Future savings from measles eradication in industrialized countries.
Carabin H; Edmunds WJ
J Infect Dis; 2003 May; 187 Suppl 1():S29-35. PubMed ID: 12721889
[TBL] [Abstract][Full Text] [Related]
7. Modeling the economic impact of different vial-opening thresholds for measles-containing vaccines.
Wedlock PT; Mitgang EA; Oron AP; Hagedorn BL; Leonard J; Brown ST; Bakal J; Siegmund SS; Lee BY
Vaccine; 2019 Apr; 37(17):2356-2368. PubMed ID: 30914223
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of potentially achievable vaccination coverage of the second dose of measles containing vaccine with simultaneous administration and risk factors for missed opportunities among children in Zhejiang province, east China.
Hu Y; Chen Y; Wang Y; Liang H
Hum Vaccin Immunother; 2018 Apr; 14(4):875-880. PubMed ID: 29252094
[TBL] [Abstract][Full Text] [Related]
9. Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis.
Nic Lochlainn LM; de Gier B; van der Maas N; van Binnendijk R; Strebel PM; Goodman T; de Melker HE; Moss WJ; Hahné SJM
Lancet Infect Dis; 2019 Nov; 19(11):1246-1254. PubMed ID: 31548081
[TBL] [Abstract][Full Text] [Related]
10. Health effects of routine measles vaccination and supplementary immunisation activities in 14 high-burden countries: a Dynamic Measles Immunization Calculation Engine (DynaMICE) modelling study.
Auzenbergs M; Fu H; Abbas K; Procter SR; Cutts FT; Jit M
Lancet Glob Health; 2023 Aug; 11(8):e1194-e1204. PubMed ID: 37474227
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of measles treatment: a systematic review.
Vo NX; Van Nguyen AT; Mai Tran HT; Thuy Truong LT; Bao Nguyen NN
J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S148-S154. PubMed ID: 31369545
[TBL] [Abstract][Full Text] [Related]
12. The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns.
Hagedorn BL; Dabbagh A; McCarthy KA
Vaccine; 2019 Sep; 37(41):6093-6101. PubMed ID: 31471145
[TBL] [Abstract][Full Text] [Related]
13. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
14. Evaluating effective measles vaccine coverage in the Malaysian population accounting for between-dose correlation and vaccine efficacy.
Kumar SS; Hartner AM; Chandran A; Gaythorpe KAM; Li X
BMC Public Health; 2023 Nov; 23(1):2351. PubMed ID: 38017415
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
16. A benefit-cost analysis of two-dose measles immunization in Canada.
Pelletier L; Chung P; Duclos P; Manga P; Scott J
Vaccine; 1998; 16(9-10):989-96. PubMed ID: 9682349
[TBL] [Abstract][Full Text] [Related]
17. Elimination of measles--South Korea, 2001-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Apr; 56(13):304-7. PubMed ID: 17410083
[TBL] [Abstract][Full Text] [Related]
18. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.
Zeng Y; Luo M; Chen J; He H; Deng X; Xie S; Fang Y
Vaccine; 2019 May; 37(23):3071-3077. PubMed ID: 31040084
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
[TBL] [Abstract][Full Text] [Related]
20. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
Thompson KM; Badizadegan ND
Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
